Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks, given with comprehensive standard of care (hospitalization ≥5 days and newly initiated or optimized oral antidepressant[s]). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale total score (primary efficacy endpoint) was analyzed using ANCOVA. Clinical Global Impression–Severity of Suicidality–revised (key secondary endpoint) was analyzed using ANCOVA on ranks of change. Results: Of 230 patients who were randomized (115 per arm), 227 received study drug and were included in efficacy/safety analyses; 184 (80.0%) completed double-blind treatment. Greater improvement in Montgomery-Asberg Depression Rating Scale total score was observed with esketamine (mean [SD]: –15.7 [11.56]) vs placebo (–12.4 [10.43]), each with standard of care, at 24 hours (least-squares mean difference [SE]: –3.9 [1.39], 95% CI: –6.60, –1.11; 2-sided P = .006). This was also noted at the earlier (4-hour) timepoint (least-squares mean difference –4.2, 95% CI: –6.38, –1.94). Patients in both treatment groups experienced rapid reduction in Clinical Global Impression–Severity of Suicidality–revised score; the between-group difference was not statistically significant. The most common adverse events among esketamine-treated patients were dizziness, dissociation, nausea, dysgeusia, somnolence, headache, and paresthesia. Conclusion: This study confirmed rapid and robust reduction of depressive symptoms with esketamine nasal spray in severely ill patients with MDD who have active suicidal ideation with intent. Trial Registration: Clinical Trials.gov identifier: NCT03097133
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least-square mean changes (±SE) from baseline for Montgomery-Asberg Depression Rating Scale (MADRS) total score during the double-blind treatment phase (mixed-effects model using repeated measures [MMRM]; observed cases). aIncludes patients who had their dose reduced due to tolerability issues. Note: Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/867338dabcaf42aca05b1ca83661094a/esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“a nasal spray form of S-ketamine was approved by the Food and Drug Administration (FDA) in the USA and by the European Medicines Agency (EMA) in Europe in 2019 [18].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Risk factors for suicide in psychiatric outpatients: A 20-year prospective study.
Brown, G. K., Beck, A. T., Steer, R. A., & Grisham, J. R. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.3.371 · Cited by 1,317 · cited 1×
“Nearly all patients with MDD who attempt or complete suicide have suicidal ideation prior to the event (Brown et al., 2000; Sokero et al., 2003).”
BackgroundValidity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Self-citationWilliams, J. B. W., & Kobak, K. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.032532 · Cited by 463 · cited 1×
“Eligible patients were between 18 and 64 years of age, met the Diagnostic and Statistical Manual of Mental Disorders–5th edition (DSM-5) criteria (American Psychiatric Association, 2013) for MDD (without psychosis) based on diagnostic assessment with the Mini International Neuropsychiatric Interview, and had a MADRS (…”
MethodPractice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.56008 · Cited by 406
The European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390 · cited 3×
“Current standard of care includes initiation or optimization of oral antidepressants and, frequently, hospitalization (American Psychiatric Association, 2003; Wasserman et al., 2012).”
Background
Research works printed but not linked: 1
- Spravato (esketamine) nasal spray. Prescribing information. 2020. Janssen Pharmaceutical Companies.
Cited by
Items 301–400 of 418
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.013
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.003
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.079
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.091
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.042
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.006
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.038
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.005
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.100
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.110
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0152
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0145
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0128
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.119
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0106
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0144
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0143
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.146
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0132
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0147
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.113
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0130
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.101
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.115
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0156
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0123
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0150
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0124
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0139
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.126
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.111
Index by Use: Commonly Prescribed For (bold for FDA approved)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.155
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.121
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0131
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.114
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.141
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0105
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0153
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.118
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0112
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0129
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.116
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0103
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0135
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0109
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.151
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0149
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.104
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0120
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0142
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0125
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0154
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.136
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.137
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0138
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0107
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.102
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.127
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.140
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0108
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.117
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.133
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0122
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0134
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0148
Borentain, S., McCormick, C. D., Joshi, K., O’Hara, M., Zhang, Q., Mulhern-Haughey, S., Richards, S., Anjo, J., Zante, D., Kewley, R. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2138354/v1
EFFECTIVENESS OF KETAMINE IN TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Borges, G. A. C., de Amorim, F. V., Alves, W. E., Amaral, T. D. B. B., da Costa, A. B. M., Silva, L. C., Caetano, M. C. G., Vasconcelos, G. F., Neto, F. O. L., Resende, G. B. D. O., et al. (2023) · International Journal of Health Science · doi:10.22533/at.ed.1593112310028
Schnell wirksame Antidepressiva
Şen, Z. D., Danyeli, L. V., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_10
Moussiopoulou, J., Slapakova, L., Kirsch, B., Mei, E. W. Y., & Schüle, C. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100110
QUETAMINA COMO MODALIDADE TERAPÊUTICA PARA ENXAQUECA E CEFALÉIA TENSIONAL: UMA REVISÃO DE LITERATURA
de Menezes, J. B. T., de Souza, S. L., Lira, M. Z. R. D. F., Oliveira, M. D. S. L., de Queiroz, A. S. S. B., de Queiroz, A. S. S. B., Filho, M. L. D. P. D. O., Leite, M. B., de Oliveira, I. C., Martins, M. A. R., et al. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i10.12107 · Cited by 1
Janski, A. M., Hristidis, V. C., Zorumski, C. F., & Conway, C. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00064-6
The Role of Rapid-Acting Antidepressants in Suicidal Crisis Management
Lengvenytė, A., Sarchiapone, M., Iosue, M., & Courtet, P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.016
Pham, G. S., & Mathew, S. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00014-8
Stahl, S. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009464772.048
Stahl, S. M., & Strawn, J. R. (2024) · doi:10.1017/9781009267526.026
REVOLUTIONIZING DEPRESSION TREATMENT: A PARADIGM SHIFT OF KETAMINE THERAPY – A SYSTEMATIC REVIEW
Kaushal, Y., GOYAL, P., & Sehgal, A. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024v17i8.51360
Kopeček, M., Andrashko, V., Knytl, P., & Horáček, J. (2024) · Psychiatrie pro praxi · doi:10.36290/psy.2024.024
Majić, T., Gouzoulis‐Mayfrank, E., & Schaub, M. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00015-0 · Cited by 3
Anhedonia: a unifying symptom and a transdiagnostic therapeutic target
Rosso, G., Pesci, N. R., PERACCHIA, S., Garrone, C., Salvo, G. D., & Maina, G. (2025) · Minerva Psychiatry · doi:10.23736/s2724-6612.24.02572-7
Jha, M. K., Teeple, A., Shepherd, J., Gillespie, A., Grant, N., Mortimer, A., Kirkman, S., Middleton‐Dalby, C., & Joshi, K. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2463975
“Esketamine, an enantiopure formulation of S -ketamine, has shown efficacy in major trials 10,11 .”
Pary, R., & Lippmann, S. (2025) · Southern Medical Journal · doi:10.14423/smj.0000000000001810
Busz, A., Schmidt, E. (. J. )., van den Brink, R., Foeken, K., de Jong, M., Mertens, J. (. B. C. )., van Noorden, M. S., Olivier, E. (. J. F. L. )., Schruers, K. R. J., Schutters, S. I. J., et al. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100905 · Cited by 2
Türkmen, C., Boesjes, R., Zandbergen, A.-F., Kamphuis, J., Viechtbauer, W., Schoevers, R. A., & van Dalfsen, J. H. (2025) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.25.1271 · Cited by 1
Zheng, R., Zheng, S., Ji, Y., Zhang, J., Li, E., Xue, X., & Yin, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5248597
Fifer, S. J., Keen, B., Herr, K. J., Chiang, C. N., & Webb, T. (2025) · Taiwanese Journal of Psychiatry · doi:10.4103/tpsy.tpsy_20_25
Skowron, C. S., Miłkowska, U., Piech, G. M., Lis, I., & Kurzyna, P. F. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0011
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 6
Xu, Y., Liu, Q., Chen, Y., Zhang, S., Wang, D., Di, B., Xu, P., Jiang, C., & Li, X. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000854
Intranasal Esketamine: The Baby in the Bathwater
Price, M. Z., & Price, R. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250168
Benhaddouch, Y., & Ammouri, A. E. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.10.005
Linan, C. B. A., Corte, A. F., Silva, J. R. G. E., Fillmann, G. P., Soares, A. B., Castro, S. C. C., Pacheco, M. A., & Spanemberg, L. (2025) · Jornal Brasileiro de Psiquiatria · doi:10.1590/0047-2085-2025-0009 · Cited by 1
Rozjabek, H., Li, N., Hartmann, H., Fu, D. J., Canuso, C. M., & Jamieson, C. (2022) · Figshare · doi:10.6084/m9.figshare.20290994
Self-citationFu, D.-J., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · Figshare · doi:10.6084/m9.figshare.23935866
Self-citationLi, C., Shi, J., Wei, S., & Jia, H. (2024) · Figshare · doi:10.6084/m9.figshare.26640316
Akutbehandlung schwerer depressiver Zustandsbilder
Tieden, S., & Kornacher, J. (2025) · Nervenheilkunde · doi:10.1055/a-2625-5639
“In einer Übersichtsarbeit wurde vor allem die therapeutische Beziehung zwischen Patienten Merke Die engmaschige Begleitung suizidaler Patienten durch den Bei fehlender Absprachefähigkeit ist . die Verlegung in ein geschütztes Setting erforderlich .”
Bogiel, Z., Machała, A., Bielak, A., Foryś, A., Kałwak, M., Kuczwalska, D., Spychalska, M., & Trocka, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4600
Menon, T., Lu, A., Arulmozhi, A., Dri, C. E., Wong, S., Teopiz, K. M., Le, G. H., Lee, S. M. L., Weissman, C. R., & McIntyre, R. S. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117036 · Cited by 1
Advances in Target Identification and Drug Development for Depression
Hu, K., Wang, X., Yu, W., Liu, Q., Cheng, Y., Song, Y., Liang, L., Liu, W., Zhang, J., Chang, S., et al. (2026) · Current Drug Targets · doi:10.2174/0113894501438555260211105139
ESKETAMINE AND DEEP BRAIN STIMULATION IN TREATMENT-RESISTANT DEPRESSION: A LITERATURE REVIEW
Wiśniewska, J., Wiśniewski, M., Buczek, W., Bartnik, P., Barzyk, K., & Pietrzak, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5003
Metadata
- Authors
- Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M.
- Affiliations
- Department of Neuroscience, Janssen Research and Development, LLC, San Diego, CA
- Janssen Research & Development (United States) (US)
- Medical University of Vienna (AT)
- Corresponding author
- Ionescu, Dawn F
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-29
- Volume
- 24
- Issue
- 1
- Pages
- 22-31
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7816667
- OpenAlex
- W3082490768
- Cited by
- 418
- References
- 28
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 41 · 2023: 49 · 2022: 43 · 2021: 31 · 2020: 161
- FWCI
- 42.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- esketamine, nasal spray, major depressive disorder, rapid-acting antidepressants, depressive symptoms, suicidality, hospitalization, adverse events, dissociation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Outcome Assessment, Health Care, Young Adult, Suicidal Ideation, Nasal Sprays, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.